| HOME >> BIOLOGY >> TECHNOLOGY |
In 2004, he returned to consultancy with Beattie Communications. In 2007, Mr. Blythe led the management buy out which launched Blythe Weigh Communications.
Paul Weigh joined Mittal Steel (now Arcelor Mittal) the world's largest steel company, in 1999, spending seven years with that firm. He left as deputy head of corporate communications, after the $42bn merger with Arcelor was successfully completed in 2006.
During his time with Mittal, Mr. Weigh was responsible for coordinating and implementing group communications at the corporate level, including the development of communication strategies to support the Group's expansion into Central and Eastern Europe (acquisitions in Romania, Czech Republic, Poland, Macedonia and Bosnia totaling in excess of $5bn), South Africa (acquisition of Iscor), North America ($4.5bn acquisition of ISG), China and India.
About Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well-defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com.
This press release contains "forward-looking statements" regarding
Immtech Pharmaceuticals, Inc.'s business, including the future prospects
for PCP. Excep
'/>"/>
| SOURCE Immtech Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |